Engineering Human Hematopoietic Stem and Progenitor Cells for Antigen Expression in Antigen-Presenting Cells.

Abstract

Gene therapy achieved through genetic manipulation and transfer of hematopoietic stem and progenitor cells (HSPC) is becoming an increasingly attractive option for personalized medicine. In the current clinical scenarios, use is restricted to overcoming genetic disorders, but it is envisioned that more diverse applications will be developed in the future. Immunotherapy of malignant disease already employs non-HSPC-based gene therapies, and there is a body of evidence that HSPC-mediated gene therapy has potential as a powerful immunotherapeutic for some diseases of immune dysregulation such as autoimmune disease and allergies. Administration of HSPC gene-engineered to encode antigen(s) induces antigen-specific immune tolerance in animal models. To translate this technology, we sought to identify whether human dendritic cells (DC) and other antigen-presenting cell populations derived from lentivirally transduced HSPC would express, process, and present antigens of interest. Lentiviral vectors were generated that encoded preproinsulin, a relevant autoantigen implicated in type 1 diabetes, or a control protein carrying a viral epitope along with reporter genes under transcriptional control of ubiquitous or antigen-presenting cell-directed promoters. In vitro, DC were differentiated from transduced HSPC and tested in antigen presentation assays using Jurkat lines carrying relevant type 1 diabetes-associated T cell receptors. In vivo, transduced HSPC were used to generate humanized mice, and the development of a range of antigen-presenting cells and their expression of lentivirus-encoded genes were determined. Antigen-presenting cell progeny of transduced HSPC expressed antigens and reporter genes both in vitro and in vivo, and in vitro-generated DC presented lentivirally encoded antigens. The studies characterize human chimerism and therapeutic gene expression in a new model and provide support for the use of HSPC-based gene therapies for immune dysregulation in humans.